{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-085558","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.560892+00:00","generated_at":"2026-06-08T05:07:13.292062+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Intensity Therapeutics reports Q3 net loss $2.3M; INT230-6 shows 93% disease control in sarcoma","bullets":["Phase 1/2 INT230-6 data in refractory soft tissue sarcoma: 93% disease control rate, survival extension ~15 months vs synthetic control.","Received Orphan Drug Designation for all three components of INT230-6 for soft tissue sarcoma.","Completed upsized IPO with full over-allotment, net proceeds $20.2M; cash $15.6M as of Sept 30, 2023.","R&D expenses $1.4M, G&A $1.1M; net operating loss $2.3M for Q3 2023.","On track to file IND for Phase 3 study in sarcoma and report Phase 2 breast cancer results by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-085558","json":"https://secwatch.observer/filing/0001213900-23-085558.json","markdown":"https://secwatch.observer/filing/0001213900-23-085558.md","text":"https://secwatch.observer/filing/0001213900-23-085558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023085558/0001213900-23-085558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000121390023085558/ea188196-8k_intensity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:07:13.292062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}